• LAST PRICE
    1.1199
  • TODAY'S CHANGE (%)
    Trending Up0.0299 (2.7431%)
  • Bid / Lots
    1.1100/ 24
  • Ask / Lots
    1.1200/ 1
  • Open / Previous Close
    1.0700 / 1.0900
  • Day Range
    Low 1.0101
    High 1.1200
  • 52 Week Range
    Low 0.5328
    High 3.9900
  • Volume
    41,006
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 1.09
TimeVolumeCYCC
09:32 ET21611.06
09:39 ET1001.05
09:44 ET50001.05
09:48 ET45001.09
09:55 ET20001.05
10:00 ET10121.054
10:06 ET1501.0849
10:11 ET22121.08
10:15 ET7001.08
10:20 ET9821.09
10:22 ET109811.1
10:31 ET10001.1188
10:44 ET4001.102
10:47 ET15401.1099
11:00 ET18051.11
11:02 ET10001.1199
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCYCC
Cyclacel Pharmaceuticals Inc
13.7M
-0.6x
---
United StatesERNA
Eterna Therapeutics Inc
13.7M
-0.5x
---
United StatesPSTV
Plus Therapeutics Inc
13.8M
-0.5x
---
United StatesNERV
Minerva Neurosciences Inc
13.5M
-0.3x
---
United StatesNDRA
ENDRA Life Sciences Inc
13.3M
-0.8x
---
United StatesMOBO
Avail Scientific Inc
14.1M
-1.9x
---
As of 2023-02-03

Company Information

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The Company is focused on the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient’s overall survival. The Company's pipeline includes Fadraciclib, CYC140 and Sapacitabine. The Fadraciclib is a cyclin dependent kinase (CDK) inhibitor selectively targeting Cyclin Dependent Kinase 2 (CDK2) and Cyclin-dependent kinase 9 (CDK9). The CYC140 is a novel, small molecule, selective and potent PLK-centric inhibitor. The Company's Sapacitabine (CYC682) is an orally available nucleoside analogue with a DNA damage response (DDR) mechanism.

Contact Information

Headquarters
200 Connell Dr Ste 1500BERKELEY HEIGHTS, NJ, United States 07922-2811
Phone
908-517-7330
Fax
866-271-3466

Executives

Independent Chairman of the Board
Christopher Henney
President, Chief Executive Officer, Director
Spiro Rombotis
Chief Financial Officer, Chief Operating Officer, Executive Vice President - Finance, Secretary, Director
Paul Mcbarron
Senior Vice President, Chief Medical Officer
Mark Kirschbaum
Independent Director
Samuel Barker

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$13.7M
Revenue (TTM)
$0.00
Shares Outstanding
12.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.14
EPS
$-1.83
Book Value
$3.73
P/E Ratio
-0.6x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.